Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nuance Doses First Patient in China Phase III Trial of Novel COPD Treatment

publication date: Apr 7, 2023

Shanghai Nuance Pharma has dosed the first patient in a China Phase III trial of a nebulized drug for COPD. Ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that offers both bronchodilator and anti-inflammatory effects. Two years ago, Nuance acquired greater China rights to the treatment from Verona Pharma of London in a $219 million agreement. In late 2022, Verona reported ensifentrine met its primary and key secondary endpoints in a US Phase III trial. The China trial is a placebo-controlled clinical study that will test ensifentrine for 24 weeks. More details....

Stock Symbol: (NSDQ: VRNA)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital